Related Experiment Video
Updated: Jan 29, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Mechanistic insights into heart failure progression and therapeutic target discovery through plasma microRNA
David de Gonzalo-Calvo1, María C García-Hidalgo1, Shambhabi Chatterjee2
1Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain; CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain.
Insights
Plasma microRNAs (miRNAs) like miR-21-5p, miR-24-3p, and miR-221-3p are linked to heart failure (HF) onset. These findings may lead to new HF prevention strategies.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Biomarker Discovery
Background:
- Early identification of heart failure (HF) pathobiological mechanisms is crucial for developing preventive strategies.
- Understanding molecular pathways driving HF pathogenesis is key to identifying therapeutic targets.
Purpose of the Study:
- To profile plasma microRNAs (miRNAs) to elucidate molecular pathways in HF pathogenesis.
- To identify potential therapeutic targets for HF by analyzing miRNA profiles.
Main Methods:
- A multicenter study involving 799 elderly patients (HOMAGE cohort) was conducted.
- Plasma miRNAs associated with incident HF were analyzed using RT-qPCR and machine learning.
- Bioinformatic analyses explored miRNA targets, including functional enrichment and drug-gene interactions.
Main Results:
- Four miRNAs (miR-21-5p, miR-24-3p, miR-132-3p, miR-221-3p) were significantly associated with incident HF.
- miR-21-5p, miR-24-3p, and miR-221-3p were identified as key miRNAs linked to HF onset.
- Enriched pathways included calcium homeostasis, cell proliferation, stress response, metabolic dysregulation, and neurohormonal activation. Five FDA-approved agonists for GABBR2 were identified.
Conclusions:
- The identified miRNAs offer a basis for future longitudinal and mechanistic HF studies.
- These findings may inform the development of novel strategies for HF prevention.
- miRNA profiling provides insights into HF pathogenesis and potential therapeutic avenues.
Background:
Identifying early pathobiological mechanisms associated with the onset and progression of heart failure (HF) could guide development of preventive strategies.
Objective:
To elucidate molecular pathways driving HF pathogenesis and identify potential therapeutic targets by profiling plasma microRNAs (miRNAs).
Methods:
Multicenter study including 799 elderly patients from HOMAGE. Incident HF was defined as the first hospitalization for HF. A panel of miRNAs implicated in HF was analyzed using RT-qPCR. Two machine learning-based feature selection methods were employed to identify contributors for HF onset. Associations between miRNA targets and HF were explored using publicly available datasets. Bioinformatic analyses were performed using the intersected targets, including functional and single-cell enrichment analyses and drug-gene interaction assessment.
Results:
After adjusting for confounders, four miRNAs (miR-21-5p, miR-24-3p, miR-132-3p, miR-221-3p) were significantly associated with incident HF in univariate analyses (FDR < 0.05). The feature selection process identified miR-21-5p, miR-24-3p and miR-221-3p as the most informative miRNAs linked to HF onset. The predicted targetome of these miRNAs encompassed 1293 transcripts, of which 32 demonstrated cardiac expression and differential levels between HF cases and controls across six different datasets. Pathway enrichment analysis revealed five key biological processes associated with HF progression: i) calcium homeostasis and signaling; ii) cell proliferation; iii) stress response and remodeling; iv) metabolic dysregulation; and v) neurohormonal activation. Drug-gene interaction analysis identified five FDA-approved agonists of the target GABBR2.
Conclusions:
The identified miRNAs provide a rationale for future longitudinal and mechanistic studies and potentially inform the development of novel strategies for HF prevention.
Related Concept Videos
MicroRNAs
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics

